InvestorsHub Logo
Followers 5
Posts 280
Boards Moderated 0
Alias Born 08/29/2015

Re: PeterKarol post# 88439

Sunday, 01/22/2017 3:34:27 PM

Sunday, January 22, 2017 3:34:27 PM

Post# of 459481
Is anyone familiar with Duexis, a drug that was granted patient protection for the combination of Ibuprofen and famotine to help insure that people taking large quantities of Ibuprofen don't burn a hole in their GI track.
These were two approved drugs that bring nothing to the table as far as new art, yet it was approved by the patient office. Just say'n.

Also the patient argument is moot. Let's say we don't have patient protection, we have how many years lead on research already reviewed. How would a company come along and replicate data without clinical trials, and get approval. That would take a long time and during that time the first to market would have a substantial lead in revenues and continued evaluation of newer improved products.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News